PODD Add to watchlist
$202.50 +1.01 (+0.50%)
After Hours: $202.50 +0.00 (+0.00%)
Last updated: Apr 15, 2026 21:15
52-Week Range
$202.50
$194.61 $202.50 $354.88

Fundamentals Overview

Insulet Corporation is near the low of its 52-week range with premium valuation, trading relatively flat today.

Valuation premium

P/E 57.9 P/B 9.4 P/S 5.26

Profitability

Net margin 9.1%

Risk (Beta)

1.47 — higher vol

Earnings & growth

EPS $3.50 Rev +11% Profit +16% vs prior qtr

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Hold — 64% confidence Risk: High Volatility — Beta 1.47. Consider smaller position size due to higher beta.

Supporting (Buy):

Analyst grade: B-

Pressures (Sell):

Sentiment weakening (2 downgrades) · 3M vs S&P 500: -28% · 3M vs Healthcare sector: -21.2% · Beta 1.47 (elevated)

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$14.26B
P/E (TTM)
57.91
EPS (TTM)
$3.50
Dividend Yield
N/A
52-Week Range
$194.61 - $354.88
Volume vs Avg
N/A
Beta
1.47

About

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle Ea...
Sector: Healthcare
Headquarters: US
Employees: 5,400
IPO Date: May 2007
Beta: 1.47 (More volatile than market)

Ratings & Grades at a Glance

Overall rating: B-. Recent institutional grades: majority downgrades. Current institutional positions: Buy: 17, Equal Weight: 1, Neutral: 2, Outperform: 7, Overweight: 2, Underweight: 1.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $-28.89; current price is $202.50. That’s a -114.3% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 57.91
PEG (TTM) N/A
P/B (TTM) 9.4
P/S (TTM) 5.26
P/FCF (TTM) 37.74
Liquidity & enterprise
Current Ratio (TTM) 2.78
Quick Ratio (TTM) 2.11
Cash Ratio (TTM) 1.05
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 9.12%
Gross margin (TTM) 71.63%
Operating margin (TTM) 17.5%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for PODD.

Analyst Sentiment at a Glance

B- Sentiment Weakening
Buy 17Equal Weight 1Neutral 2Outperform 7Overweight 2Underweight 1
1 upgrade, 2 downgrades
Price Target Consensus
Current $202.50
Median $335.00
Consensus $348.92
Low consensus $286.00
High consensus $435.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Goldman Sachs maintain Buy Buy 2026-04-09
Citigroup downgrade Buy Neutral 2026-04-07
Citigroup maintain Buy Buy 2026-03-11
Oppenheimer maintain Outperform Outperform 2026-02-19
JP Morgan maintain Overweight Overweight 2026-02-19
Truist Securities maintain Buy Buy 2026-02-19
Citigroup maintain Buy Buy 2026-02-19
Goldman Sachs maintain Buy Buy 2026-02-19
Evercore ISI Group maintain Outperform Outperform 2026-02-19
Leerink Partners maintain Outperform Outperform 2026-02-19
Canaccord Genuity maintain Buy Buy 2026-02-19
Bernstein maintain Outperform Outperform 2026-02-19
BTIG maintain Buy Buy 2026-02-18
Stifel maintain Buy Buy 2026-02-04
Barclays downgrade Equal Weight Underweight 2026-01-12
Bernstein maintain Outperform Outperform 2026-01-09
Truist Securities maintain Buy Buy 2025-12-18
Canaccord Genuity maintain Buy Buy 2025-12-17
Canaccord Genuity maintain Buy Buy 2025-11-24
BTIG maintain Buy Buy 2025-11-21
Truist Securities maintain Buy Buy 2025-11-21
RBC Capital maintain Outperform Outperform 2025-11-21
UBS upgrade Neutral Buy 2025-11-19
BTIG maintain Buy Buy 2025-11-13
UBS maintain Neutral Neutral 2025-11-07
Barclays maintain Equal Weight Equal Weight 2025-11-07
Truist Securities maintain Buy Buy 2025-11-07
Wells Fargo maintain Overweight Overweight 2025-11-07
RBC Capital maintain Outperform Outperform 2025-11-07
Canaccord Genuity maintain Buy Buy 2025-11-07